DelveInsight’s “Chronic Pain Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Chronic Pain market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Chronic Pain drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Chronic Pain treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Chronic Pain: An Overview
Chronic Pain refers to pain persisting beyond three months. It may escalate over time and resurface intermittently, extending beyond the expected recovery period and impacting one’s overall wellness. Ordinarily, the pain subsides as damaged tissue heals, contingent upon addressing the underlying cause. Yet, chronic pain can persist despite tissue healing, defying clear biological explanations. Its duration, often linked to its origin, might extend to six months or beyond. In certain cases, painful conditions could endure for years.
The primary origins of chronic pain encompass prevalent conditions such as lower back pain, migraines, neuralgia (neuropathic pain), fibromyalgia (musculoskeletal pain), cancer-related pain, post-operative discomfort, as well as arthritic pain stemming from osteoarthritis and rheumatoid arthritis, among others. Chronic pain’s repercussions extend beyond the physical, inducing notable psychological and emotional distress, often constraining an individual’s capacity for complete functionality. Particularly in elderly individuals, chronic pain surfaces as a frequent grievance. It’s possible for an individual to contend with multiple chronic pain ailments concurrently. Persisting pain might persist long after an injury or emerge without discernible causation. In some scenarios, several contributing factors might be at play.
Frequently, chronic pain gives rise to vegetative indicators (such as fatigue, disrupted sleep, reduced appetite, loss of interest in food, weight decline, decreased sexual drive, and constipation) that manifest progressively. The ceaseless and unrelenting nature of pain can pave the way for the emergence of depression and anxiety, impeding nearly all aspects of daily life. Individuals might curtail their physical engagement, retreat from social interactions, and become overly focused on their physical well-being. The resulting psychological and social limitations can be profound, leading to a state of almost complete dysfunction.
Chronic Pain Market Key Facts
-
The chronic pain market size in the seven major markets was over USD 20 billion in 2021.
-
The prevalent cases of chronic pain associated in 7MM countries were around 174 million in 2021.
-
According to the Centers for Disease Control and Prevention, an estimated 20.4% (50.0 million) of US adults had chronic pain and 8.0% of US adults (19.6 million) had high-impact chronic pain, with a higher prevalence of both chronic pain and high-impact chronic pain reported among women, older adults, previously but not currently employed adults, adults living in poverty, adults with public health insurance, and rural residents.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Chronic Pain pipeline therapies. It also thoroughly assesses the Chronic Pain market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Chronic Pain drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Chronic Pain Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Chronic Pain epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Chronic Pain epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Chronic Pain Epidemiology, Segmented as –
-
Total Prevalent Cases of Chronic Pain
-
Severity-Specific Cases of Chronic Pain
-
Age-Specific Cases of Chronic Pain
-
Cause-Specific Cases of Chronic Pain
Chronic Pain Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Chronic Pain market or expected to be launched during the study period. The analysis covers the Chronic Pain market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Chronic Pain drugs based on their sale and market share.
The report also covers the Chronic Pain pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Chronic Pain companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Chronic Pain Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/chronic-pain-market
Chronic Pain Therapeutics Analysis
There are multiple pharmacological, adjunct, non-pharmacological, and interventional treatments for chronic, severe, and persistent pain. The list of pharmacological options for chronic pain is extensive. This list includes non-opioid analgesics such as non-steroidal anti-inflammatories (NSAIDs), acetaminophen, and aspirin. Medications such as tramadol, opioids, and antiepileptic drugs (gabapentin or pregabalin) can be useful. Furthermore, antidepressants such as tricyclic antidepressants and SNRIs, topical analgesics, muscle relaxers, N-methyl-d-aspartate (NMDA) receptor antagonists, and alpha 2 adrenergic agonists are also possible pharmacological therapies.
Effective pain management, particularly for chronic pain, is best achieved through a patient-centered, multidisciplinary approach that may include pharmacotherapy. Generally, two broad categories of medications are used for pain management: nonopioids and opioid classes of medications. Drugs recently approved for the treatment of chronic pain due to different indications include Emgality (galcanezumab-gnlm), Aimovig (Eptinezumab), Tarlige (Mirogabalin besylate), Aimovig (Erenumab-aooe), Ajovy (Fremanezumab), Vyepti (Eptinezumab), and Pennsaid gel.
Chronic Pain Companies Actively Working in the Therapeutics Market Include
AbbVie, Paradigm Biopharmaceuticals Ltd., Noven Pharmaceuticals, Inc., Pfizer, Anika Therapeutics, Inc., Biogen, Tonix Pharmaceuticals, Inc., Taiwan Liposome Company, Centrexion Therapeutics, Braeburn Pharmaceuticals, Regeneron, Teva Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Vertanical GmbH, and others.
Emerging and Marketed Chronic Pain Therapies Covered in the Report Include:
-
Aimovig/Erenumab (Amgen/Novartis)
-
Ajovy/Fremanezumab (Teva Pharmaceuticals)
-
Ampion (Ampio Pharmaceuticals)
-
Atogepant (Allergan [acquired by ABBVie])
-
Emgality/Galcanezumab (Elli Lilly and Company)
-
Fasinumab/REGN475 (Regeneron Pharmaceuticals/Teva Pharmaceuticals/Mitsubishi Tanabe Pharma Corporation)
-
Rexlemestrocel/MPC-06-ID (Gruenthal/Mesoblast)
-
Tanezumab (Pfizer/Eli Lilly and Company)
-
Tarlige/Mirogabalin (Daiichi Sankyo)
-
Vyepti/ Eptinezumab (Alder Biopharmaceuticals [Acquired by Lundbeck])
And Many Others
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/chronic-pain-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Chronic Pain Competitive Intelligence Analysis
4. Chronic Pain Market Overview at a Glance
5. Chronic Pain Disease Background and Overview
6. Chronic Pain Patient Journey
7. Chronic Pain Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Chronic Pain Treatment Algorithm, Current Treatment, and Medical Practices
9. Chronic Pain Unmet Needs
10. Key Endpoints of Chronic Pain Treatment
11. Chronic Pain Marketed Therapies
12. Chronic Pain Emerging Drugs and Latest Therapeutic Advances
13. Chronic Pain Seven Major Market Analysis
14. Attribute Analysis
15. Chronic Pain Market Outlook (In US, EU5, and Japan)
16. Chronic Pain Companies Active in the Market
17. Chronic Pain Access and Reimbursement Overview
18. KOL Views on the Chronic Pain Market
19. Chronic Pain Market Drivers
20. Chronic Pain Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/chronic-pain-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Myofascial Pain Syndrome Market
“Myofascial Pain Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Myofascial Pain Syndrome market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Myofascial Pain Syndrome market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/https://www.delveinsight.com/oncology